| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,262,000 |
| Market
Cap: |
12.96(B) |
| Last
Volume: |
329,299 |
Avg
Vol: |
421,496 |
| 52
Week Range: |
$205.19 - $272.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile United Therapeutics is a biotechnology company. Through its subsidiary, Lung Biotechnology PBC, Co. is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Co. markets and sells the following commercial therapies to treat pulmonary arterial hypertension: Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, for the treatment of high-risk neuroblastoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
561,075 |
601,080 |
663,963 |
1,859,458 |
| Total Sell Value |
$136,150,891 |
$145,221,114 |
$159,349,326 |
$455,394,009 |
| Total People Sold |
8 |
8 |
8 |
11 |
| Total Sell Transactions |
65 |
74 |
86 |
265 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Patusky Christopher |
|
– • – |
2023-05-10 |
4 |
D |
$212.24 |
$424,480 |
D/D |
(2,000) |
1,684 |
|
- |
|
| Patusky Christopher |
|
– • – |
2023-05-10 |
4 |
OE |
$88.03 |
$176,060 |
D/D |
2,000 |
3,684 |
|
- |
|
| Mesa Nilda |
|
– • – |
2023-05-05 |
4 |
S |
$214.81 |
$80,337 |
D/D |
(374) |
5,806 |
|
-3% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2023-05-04 |
4 |
AS |
$215.15 |
$1,294,903 |
D/D |
(6,000) |
36,599 |
|
3% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2023-05-04 |
4 |
OE |
$120.26 |
$721,560 |
D/D |
6,000 |
42,599 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-05-02 |
4 |
AS |
$227.79 |
$1,828,685 |
D/D |
(8,000) |
130 |
|
-2% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-05-02 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-05-01 |
4 |
AS |
$229.84 |
$1,851,202 |
D/D |
(8,000) |
130 |
|
-3% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-05-01 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-28 |
4 |
AS |
$227.93 |
$1,834,584 |
D/D |
(8,000) |
130 |
|
-3% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-28 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-27 |
4 |
AS |
$224.12 |
$1,812,022 |
D/D |
(8,000) |
130 |
|
-2% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-27 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-26 |
4 |
AS |
$225.60 |
$1,808,056 |
D/D |
(8,000) |
130 |
|
-0% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-26 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-25 |
4 |
AS |
$224.64 |
$1,808,313 |
D/D |
(8,000) |
130 |
|
1% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-25 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-24 |
4 |
AS |
$227.67 |
$1,829,145 |
D/D |
(8,000) |
130 |
|
-2% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-24 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-21 |
4 |
AS |
$226.57 |
$1,830,557 |
D/D |
(8,000) |
130 |
|
-1% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-21 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
| Dwek Raymond |
|
– • – |
2023-04-21 |
4 |
D |
$230.76 |
$461,520 |
D/D |
(2,000) |
0 |
|
- |
|
| Dwek Raymond |
|
– • – |
2023-04-21 |
4 |
OE |
$63.90 |
$127,800 |
D/D |
2,000 |
2,000 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-20 |
4 |
AS |
$223.76 |
$1,799,227 |
D/D |
(8,000) |
130 |
|
2% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2023-04-20 |
4 |
OE |
$113.08 |
$904,640 |
D/D |
8,000 |
8,130 |
|
- |
|
2674 Records found
|
|
Page 8 of 107 |
|
|
2.04 (0.75%) 
